Palghar-based pharma formulations manufacturer exporting generics to 52 countries, diversifying into pet care, nutraceuticals and mobility.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 |
| Reserves | 37 | 39 | 64 | 92 | 117 | 137 | 153 | 273 |
| Borrowings | 35 | 40 | 53 | 87 | 106 | 166 | 171 | 222 |
| Other Liabilities | 65 | 79 | 66 | 74 | 81 | 179 | 136 | 141 |
| Total Liabilities | 141 | 162 | 187 | 257 | 308 | 487 | 464 | 642 |
| AssetsFixed Assets | 31 | 30 | 32 | 39 | 47 | 53 | 65 | 118 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 2 |
| Other Assets | 110 | 131 | 155 | 218 | 260 | 433 | 397 | 522 |
| Total Assets | 141 | 162 | 187 | 257 | 308 | 487 | 464 | 642 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 1 | -11 | 0 | -2 | -14 | 0 | -21 | 16 |
| Cash from Investing | -5 | -1 | -1 | -4 | -9 | -8 | -6 | -74 |
| Cash from Financing | 4 | 14 | -1 | 7 | 25 | 6 | 26 | 122 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | -4 | -12 | -1 | -7 | -24 | -8 | -27 | -57 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (61.6×) and current (36.2×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 50.8% growth and a 36× exit, ₹900 only delivers your return if you pay ₹3,574. The price is currently baking in 18% growth.
EPS grows 50.8%/yr for 5 years, then fades to 6% over 2, exits at 36×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 50.8% | 37.52 |
| FY28 | 50.8% | 56.58 |
| FY29 | 50.8% | 85.32 |
| FY30 | 50.8% | 128.66 |
| FY31 | 50.8% | 194.02 |
| FY32 | 28.4% ·fade | 249.13 |
| FY33 | 6.0% ·fade | 264.08 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.